NCT06830889 - A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy | Biotech Hunter

Enrollment

1,450

Participants

Timeline

Start Date

June 9, 2025

Primary Completion Date

October 31, 2031

Study Completion Date

December 31, 2031

Conditions

HER2-positive Breast Cancer

Interventions

DRUG

BL-M07D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

T-DM1

Administration by intravenous infusion for a cycle of 3 weeks.

Trial Locations (2)

RECRUITING

Jiangsu Province Hospital, Nanjing

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY